| Cat. No. |
Product Name |
Information |
| PC-Ab1024 |
Cetuximab
|
Cetuximab binds specifically to the extracellular domain of the human EGFR, and down-regulates constitutively activated EGFR vIII on the cell surface. It has also been investigated in advanced colorectal cancer, EGFR-expressing non-small cell lung cancer (NSCLC), and unresectable squamous cell skin cancer. Cetuximab is also indicated for K-Ras wild-type, EGFR-expressing, metastatic colorectal cancer as determined by an FDA-approved test in combination with FOLFIRI, a chemotherapy combination th |
| PC-Ab1023 |
Muromonab
|
Muromonab-CD3 (Orthoclone-OKT3) is the first mAb recognizing CD3 surface antigen on human T cells, functions as an immunosuppressant. . |
| PC-Ab1022 |
SP34-2
|
. |
| PC-Ab1021 |
Ivuxolimab
|
PF-04518600 selectively binds to and activates OX40, activating the dormant immune response, which then may help fight cancer cells. The activation of OX40 could also suppress the activity of regulatory-T cells, further increasing the immune response against cancer cells.. |
| PC-Ab1020 |
Fresolimumab
|
Fresolimumab (GC1008) is a pan-TGFβ neutralizing antibody, blocks TGFβ-mediated pSMAD signaling, and TGFβ-mediated suppression of T cells and NK cells.. |
| PC-Ab1019 |
Secukinumab
|
Secukinumab (Cosentyx) is a human monoclonal antibody designed for the treatment of uveitis, rheumatoid arthritis, ankylosing spondylitis, and psoriasis. Secukinumab is an interleukin-17A (IL-17A) inhibitor By targeting IL-17A. Secukinumab has shown excellent efficacy in psoriasis by normalizing skin histology.. |
| PC-Ab1018 |
[Ipilimumab
|
Ipilimumab is a fully human IgG1κ antibody that binds to CTLA-4 (cytotoxic T lymphocyte-associated antigen 4), a molecule on T-cells that is indicated for unresectable or metastatic melanoma. The absence or presence of CTLA-4 can augment or suppress the immune system’s T-cell response in fighting disease. Ipilimumab is designed to block the activity of CTLA-4, thereby sustaining an active immune response in its attack on cancer cells. The proposed mechanism of action is indirect, and may be thro |
| PC-Ab1017 |
Sabatolimab
|
Binds and blocks the interaction TIM3/PtdSer (Kd=0.16 nM, PtdSer Blocking IC50=6.4 nM) , restore effector T cell activity to promote antitumor immunity by altering myeloid cells in tumor microenvironment. TIM-3 may synergize with PD-1 blockade by enhancing or altering the innate immune response and may form part of a resistance mechanism to PD-1 blockade.. |
| PC-Ab1016 |
Zolbetuximab
|
Zolbetuximab is a first-in-class chimeric IgG1 mAb that specifically binds to Claudin 18 splice variant 2 (CLDN18.2) on the cell surface and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Claudin-18 (CLDN18) is a highly specific TJ component of the stomach. It is expressed in foetal and in adult normal gastric mucosa. |
| PC-Ab1015 |
Zolbetuximab
|
Zolbetuximab is a first-in-class chimeric IgG1 mAb that specifically binds to Claudin 18 splice variant 2 (CLDN18.2) on the cell surface and mediates cell death through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Claudin-18 (CLDN18) is a highly specific TJ component of the stomach. It is expressed in foetal and in adult normal gastric mucosa. |
| PC-Ab1014 |
Relatlimab
|
Relatlimab (BMS-986016) is a human IgG4 anti-LAG3 blocking mAb. Combination of LAG-3 with the immunomodulatory drug (IMiD) lenalidomide significantly increased IL-2 production by T cells and antibody-dependent cytotoxicity (ADCC) mediated by NK cells. These datas provide new insights into the potential anti-leukemic effects. |
| PC-Ab1013 |
Anti-mouse PD-L1, 10F.9G2
|
10F.9G2 is anti-PD-L1 mAb 10F.9G2 blocks both PD-L1:B7-1 and PD-L1:PD-1 interactions. This‘dual-blocker’ mAb rapidly induced diabetes in NOD mice of both ages. . |
